Clinical Trial Update: 3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating Ikervis (ciclosporin ophthalmic emulsion) in dry eye disease with severe keratitis has completed, with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease
• Keratitis

Drugs mentioned

• Ikervis (ciclosporin ophthalmic emulsion)

Snippet

Sponsor: Santen SAS | Conditions: Dry Eye Disease With Severe Keratitis | Phase 3 | Status: COMPLETED | Results posted: 2024-08-28